- |||||||||| carbidopa/levodopa / Generic mfg.
Clinical, P1 data, Journal: The safety and tolerability of levodopa eye drops for the treatment of ocular disorders: A randomized first-in-human study. (Pubmed Central) - Nov 16, 2022
These results indicate that topical levodopa/carbidopa is safe and tolerable to the eye, paving the way for future studies on the efficacy of this novel ophthalmic formulation in the treatment of human myopia. The findings of this study have implications not only for the treatment of myopia, but in a number of other visual disorders (i.e., amblyopia, diabetic retinopathy, and age-related macular degeneration) in which levodopa has been identified as a potential clinical intervention.
- |||||||||| Trial completion date, Trial primary completion date: Substance Abuse Pre-Treatment Screening Study (clinicaltrials.gov) - Nov 1, 2022
P=N/A, N=7500, Recruiting,
The cause of creatine kinase elevation cannot be explained by abnormal strong muscle contraction nor inflammation. Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
- |||||||||| carbidopa/levodopa / Generic mfg.
Journal: Assessing the Neurotoxicity of a Sub-Optimal Dose of Rotenone in Zebrafish (Danio rerio) and the Possible Neuroactive Potential of Valproic Acid, Combination of Levodopa and Carbidopa, and Lactic Acid Bacteria Strains. (Pubmed Central) - Oct 28, 2022
Overall, the selected concentrations were enough to trigger particular behavioral patterns as reflected by our parameters of interest (swimming distance (mm), velocity (mm/s), and freezing episodes (s)), but sequential testing is mandatory to decipher whether they exert an inhibitory role following ROT exposure. In this way, we further offer data into how ROT may trigger a PD-related phenotype and the possible beneficial role of VPA, LEV+CARB, and PROBIO in re-establishing homeostasis in Danio rerio.
- |||||||||| carbidopa/levodopa / Generic mfg.
Review, Journal: Multifunctional role of natural products for the treatment of Parkinson's disease: At a glance. (Pubmed Central) - Oct 28, 2022
Anti-Parkinson drugs like dopamine (DA) agonists, levodopa, carbidopa, monoamine oxidase type B inhibitors and anticholinergics are used to replace DA in the current treatment model...The use of natural remedies, especially those derived from plants, to treat PD has been on the rise. This article examines the fundamental characteristics of medicinal plants and the bioactive substances found in them that may be utilized to treat PD.
- |||||||||| carbidopa/levodopa / Generic mfg.
Review, Journal: Molecular understanding of the translational models and the therapeutic potential natural products of Parkinson's disease. (Pubmed Central) - Oct 22, 2022
To date, the mainstream treatment of Parkinson's disease has been achieved by alleviating its associated morbid symptoms, such as the use of levodopa, carbidopa, dopamine receptor agonists, monoamine oxidase type B inhibitors, anticholinergic drugs, etc. However, strong side effects, even toxicity, have been reported after using these drugs, with reduced effectiveness over time...In this review, we have compiled several natural plant compounds and classified the currently reported compounds for therapeutic use based on their structural parent nuclei and constituent elements. We wish to inspire new ideas for the treatment of Parkinson's disease by summarizing their mechanisms.
- |||||||||| carbidopa/levodopa / Generic mfg.
Journal, HEOR: Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson's Disease. (Pubmed Central) - Oct 19, 2022
At 80 weeks there were fewer patients with motor response fluctuations in the group that had started levodopa earlier. From an economic point of view, this study suggests that early treatment with levodopa is not more expensive than delayed treatment with levodopa.
- |||||||||| Triolex (NE3107) / BioVie
Enrollment closed: NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa (clinicaltrials.gov) - Oct 19, 2022
P1/2, N=40, Active, not recruiting,
Patients with advanced PD receiving LCIG showed significant sustained improvements in the burden of dyskinesia and non-motor symptoms up to 24 months after initiation. Recruiting --> Active, not recruiting
- |||||||||| carbidopa/levodopa / Generic mfg.
Photosensitivity as a Presenting Feature in Progressive Supranuclear Palsy () - Oct 17, 2022 - Abstract #ANA2022ANA_609;
She had been started on a Sinemet trial for 2 weeks and had not shown any improvement in her symptoms... Given the midbrain degeneration in PSP, it is worthwhile to explore the relationship between photosensitivity as a presenting feature and correlation with degree of midbrain atrophy in future studies.
- |||||||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Parkinson’s Disease Patient Characteristics in a US Real-World Study of Opicapone () - Oct 17, 2022 - Abstract #ANA2022ANA_605;
While the study was conducted during the ongoing pandemic and investigators could initiate treatment via telemedicine, most investigators elected to initiate patients on opicapone with an in-person visit. Findings from OPTI-ON will further characterize the PD population treated with opicapone and real-world clinician- and patient-reported outcomes data in the US will complement results from previous controlled clinical trials.
- |||||||||| carbidopa/levodopa / Generic mfg., carbidopa / Generic mfg.
Nanoencapsulation of Levodopa and Carbidopa for the Treatment of Parkinson’s Disease () - Oct 17, 2022 - Abstract #ANA2022ANA_603;
Findings from OPTI-ON will further characterize the PD population treated with opicapone and real-world clinician- and patient-reported outcomes data in the US will complement results from previous controlled clinical trials. LD and CD can be encapsulated into both lipid NPs and PLGA NPs, with a high encapsulation efficiency in PLGA NPs, while remaining stable for 24 hours.
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial suspension: Effects of 5HTP and LDOPA on CNS Excitability After SCI (clinicaltrials.gov) - Oct 17, 2022
P2/3, N=30, Suspended,
LD and CD can be encapsulated into both lipid NPs and PLGA NPs, with a high encapsulation efficiency in PLGA NPs, while remaining stable for 24 hours. Recruiting --> Suspended
- |||||||||| carbidopa/levodopa / Generic mfg.
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Secondary to Untreated Parkinson Disease (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2324;
Parkinsonism was confirmed by outpatient neurology who started Carbidopa/Levodopa...In contrary to literature, SIADH resolved with anti-Parkinson treatment which supports Parkinson’s disease as a causal mechanism. As dose increased of anti-Parkinson’s agent, urine osmolality improved and extrapyramidal symptoms resolved.
- |||||||||| sertraline / Generic mfg.
Effective treatment of an adolescent with generalized dystonia comorbid with major depressive disorder with sertraline (Poster area [ONLINE]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_1349;
Sodium valproate was prescribed but her depressed and irritable mood, reference and persecutory delusions, and impulsive behaviours persisted...Recent studies reinforce the concept that psychiatric disorders commonly observed in dystonic patients are intrinsic to the neurobiology of dystonia, which may involve the dopaminergic and 5-HT neurotransmitter systems. Treating depression with antidepressants or other biological treatments in dystonia should be considered strongly.
- |||||||||| Nuplazid (pimavanserin) / Acadia Pharma
Psychiatric disorders induced by antiparkinsonics (Poster area [ONLINE]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_1228;
Plus, it does not worsen motor function [3-4]. Pimavanserin is not available in Portugal, however it could have also been chosen as it is also approved for treating PDP [3,5].
- |||||||||| carbidopa/levodopa / Generic mfg., pramipexole IR / Generic mfg.
Longitudinal oral administration of centrally-acting drugs to nonhuman primates (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_2563;
This methodology is an effective means for longitudinal oral administration of anti-Parkinson drugs or placebo to nonhuman primates. The technique may be adapted to studies of alternative centrally-active agents.
- |||||||||| carbidopa/levodopa / Generic mfg.
Novel robotics-treadmill-platform application to improve walking in a person with Parkinson’s disease: a case report (Station 4) - Oct 2, 2022 - Abstract #ACRM2022ACRM_816;
An implicit learning approach, combined with a robotic treadmill, may enable individuals to perform challenging tasks without fear of physical harm and to develop strategies for safe mobility in their environment Learning Objectives: better understand the potential for recovery of walking balance in individuals with Parkinson’s disease. learn the importance of a robotic treadmill environment that provides safety from falls, freedom of movement, self-intentional pacing, and body weight support.
- |||||||||| carbidopa/levodopa / Generic mfg.
Journal: Neuropsychological profile associated with an alpha-synuclein gene (SNCA) duplication. (Pubmed Central) - Sep 29, 2022
Follow-up evaluations showed rapid cognitive decline that far surpassed the patient's Parkinsonism, which responded well to carbidopa-levodopa...This case study is the first to describe this rare phenotype in terms of its full neuropsychological profile and trajectory. The case highlights the value of a transdisciplinary evaluation and treatment and brings up important ethical and practical issues that should be considered when working with patients who have suspected or known genetic disorders.
- |||||||||| carbidopa/levodopa / Generic mfg.
Electrophysiology marker of levodopa induced dyskinesia in Parkinson disease (Poster Station: 24) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_1372;
Electrophysiology markers of LID could one day be used in diagnosis and monitoring. In addition, these biomarkers could contribute to the advancement of closed loop deep brain stimulation.
- |||||||||| carbidopa/levodopa / Generic mfg.
A case of levodopa responsive parkinsonism due to methanol toxicity, an impact of COVID-19 crisis (Poster Station: 4) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_1115;
She was started on levodopa-carbidopa, dopamine agonists and was injected with botulinum toxin... Hence we report a case of levodopa responsive secondary parkinsonism due to methanol toxicity in background of alcohol crisis due to economic breakdown during COVID 19 pandemic.
- |||||||||| carbidopa/levodopa / Generic mfg.
Antidyskinetic Effects of CaV1.3 Calcium Channel Gene Silencing in Aged Male and Female Parkinsonian Macaques (Poster Station: GPT 12) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_1051;
Levodopa:carbidopa (25:100; p.o., b.i.d., M-Fr) was administered at escalating doses (20mg/kg for 3.5mo; 30mg/kg for 1mo; 40mg/kg for 1mo)... Decreasing striatal expression of CaV1.3 in aged male & female NHPs can provide near complete protection against LID induction when gene therapy is administered to NHP with long-standing severe parkinsonian disability and prior to introduction of levodopa.
- |||||||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Effects of Once-Daily Opicapone 50 mg on COMT activity: A Pooled Post-hoc Analysis of Two Phase 1 Studies (Poster Station: 11) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_1008;
Adding once-daily OPC 50 mg to CD/LD resulted in substantial S-COMT inhibition with reduced variability regardless of disease state, age, gender, ethnicity, or other factors. In all participants regardless of demographics, COMT inhibition shown by OPC with CD/LD leads to more consistent daily LD exposure, which continues to be a challenge and goal in treating PD.
- |||||||||| carbidopa/levodopa / Generic mfg.
Nutritional Status in Advanced Parkinson’s Disease: Preliminary Results. (Poster Station: 3) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_968;
All groups presented weight loss. A higher sample size is necessary to verify that good nutritional support is important to improve the quality of life of patients with PD
- |||||||||| Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
Bullous skin lesions following introduction of safinamide in a woman with Parkinson’s disease (Poster Station: 1) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_955;
Whereas no histopathological examination was performed to confirm the diagnosis, it nevertheless raises the possibility that safinamide may cause drug-induced pemphigoid, at least in some individuals who previously have had this condition. Further case reports like this one, with histopathological confirmation, are necessary to confirm this possibility.
- |||||||||| Functional dystonia on a 46 year-old woman (Poster Station: 10) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_584;
She was diagnosed with functional dystonia and we started management with patient education and citalopram 20 mg and quetiapine 25 mg daily. One week after the initial evaluation the patient was seen at our clinic and the dystonia was fully resolved.
- |||||||||| carbidopa/levodopa / Generic mfg., rivastigmine / Generic mfg.
Spinocerebellar ataxia 21 and phenotypic variability within a family (Poster Station: 2) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_409;
One week after the initial evaluation the patient was seen at our clinic and the dystonia was fully resolved. SCA21 is a slowly progressive autosomal dominant spinocerebellar ataxia with variable neurodevelopmental phenotypes including multiple movement disorders within the same variant.
- |||||||||| carbidopa/levodopa / Generic mfg.
Availability and accessibility of medicines for patients with Parkinson’s disease in Kyrgyzstan (Poster Station: 22) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_115;
However, the major problem is caused by lack of registration of APM, affordability due to low income, and lack of proper social and financial support from the government. There is an urgent need for the development of health policies addressing problems of PD patients in Kyrgyzstan.
- |||||||||| carbidopa/levodopa / Generic mfg., amantadine / Generic mfg.
Journal: Study of the Effects of Nicotine and Caffeine for the Treatment of Parkinson's Disease. (Pubmed Central) - Sep 21, 2022
We could identify the potential therapeutic aspects of these natural products to prevent the onset of PD. This work may therefore be considered to be the first of its kind which would take into consideration the environmental toxicological approach in designing natural product inhibitors against the onset of PD.
- |||||||||| carbidopa/levodopa / Generic mfg.
Review, Journal: Sequestration of Inflammation in Parkinson's Disease via Stem Cell Therapy. (Pubmed Central) - Sep 18, 2022
Gold standard treatment includes exogenous dopamine therapy in the form of levodopa-carbidopa, or surgical intervention with a deep brain stimulator to the subcortical basal ganglia...Alternative strategies, such as exercise and diet modifications, also appear to play a significant role in facilitating endogenous and exogenous stem cells to induce an anti-inflammatory response, and thus are of unique interest to neuroinflammatory conditions including Parkinson's disease. Treating patients with current gold standard therapeutics and adding adjuvant stem cell therapy, alongside the aforementioned lifestyle modifications, may ideally sequester inflammation and thus halt neurodegeneration.
- |||||||||| Triolex (NE3107) / BioVie
Trial completion date, Trial primary completion date: NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa (clinicaltrials.gov) - Sep 16, 2022
P1/2, N=40, Recruiting,
Treating patients with current gold standard therapeutics and adding adjuvant stem cell therapy, alongside the aforementioned lifestyle modifications, may ideally sequester inflammation and thus halt neurodegeneration. Trial completion date: Aug 2022 --> Nov 2022 | Trial primary completion date: Aug 2022 --> Nov 2022
- |||||||||| metoclopramide / Generic mfg.
METOCLOPRAMIDE-INDUCED RESPIRATORY DYSKINESIA: A CASE REPORT (Convention Center Exhibit Hall: Rapid Area 1A) - Sep 11, 2022 - Abstract #CHEST2022CHEST_3725;
Misdiagnosis of respiratory dyskinesia can result in significant morbidity and mortality. A high degree of clinical suspicion can avoid lengthy, expensive workups and potential management mishaps.
|
